GET DAILY SIGNALSWhy Is Adagio Medical Holdings (ADGM) Stock Down -29.81% Today?
Key Takeaways
- ADGM shares tumbled roughly 30%, sliding to about $0.06 from a prior close of $0.0862.
- The primary catalyst was the company's announced 1-for-30 reverse stock split, aimed at regaining Nasdaq listing compliance.
- Secondary drivers include Nasdaq minimum-bid-price noncompliance, delisting risk, ongoing cash burn, and share dilution from convertible note conversions.
- The move reflects broader distress sentiment around this micro-cap medical-device name rather than a single fundamental data release.
- Traders are watching the split's effective date, upcoming Q3 earnings, and the company's strategic-alternatives process.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading ideas across the market on Trending AI Robots.
Opening Summary
Adagio Medical Holdings, Inc. (ADGM), a Laguna Hills, California-based medical technology company developing ultra-low temperature cryoablation systems for treating cardiac arrhythmias, saw its stock fall sharply in Thursday's session. Shares dropped about 29.8% to near $0.0605, down from a prior close of $0.0862, as investors reacted to a newly announced reverse stock split and persistent concerns about the company's Nasdaq listing status and liquidity position.
Reverse Stock Split Announcement
The dominant catalyst behind the selloff was the company's disclosure of a 1-for-30 reverse stock split. In a filing dated November 4, 2026, ADGM said it would amend its certificate of incorporation to combine every thirty outstanding common shares into one, effective at 5:00 p.m. Eastern Time on November 6, 2026, with trading on a split-adjusted basis expected when the market opens November 9, 2026.
Reverse splits are frequently interpreted by the market as a distress signal rather than a value-creating event. While the maneuver mechanically raises the per-share price, it does not change the company's underlying market capitalization, and it can invite additional selling pressure as holders reassess the outlook. That dynamic weighed heavily on the stock Thursday, driving the sharp percentage decline.
Nasdaq Compliance and Balance-Sheet Pressure
The reverse split is a direct response to a Nasdaq minimum-bid-price deficiency. ADGM previously disclosed it had received notice that its shares had closed below the $1.00 minimum bid price for 30 consecutive trading days, giving the company until December 9, 2026, to regain compliance. The board's decision to implement the 1-for-30 split was approved by stockholders in October and is intended to lift the trading price back above the threshold.
Compounding the negative sentiment, the company has reported ongoing operating losses and limited cash, has disclosed a "going concern" warning, and announced earlier this year that it was reviewing strategic alternatives. Recent conversions of its 13% Senior Secured Convertible Notes have also added to the share count, a dilutive dynamic that weighs on a micro-cap already trading near the low end of its 52-week range.
Market Context and Trading Activity
The move reflects the volatility typical of low-priced, thinly traded micro-caps. ADGM carries a market capitalization of only about $2 million, meaning even modest selling can translate into outsized percentage swings. Trading volume has remained light relative to earlier periods, and the stock has been trending lower for months as regulatory, funding, and strategic uncertainties accumulated. The decline Thursday was driven by company-specific corporate actions rather than a broad move in medical-device indices or the wider market.
What Comes Next for ADGM
Investors are focused on several near-term milestones. The reverse split becomes effective November 6, 2026, with split-adjusted trading expected to begin November 9, and the company still faces its December 9 Nasdaq compliance deadline. ADGM is also expected to report third-quarter results in the coming days, with analysts anticipating a continued net loss. The outcome of the board's strategic-alternatives review, progress on its vCLAS cryoablation system's FDA premarket approval application, and any further financing or dilution events remain key uncertainties that could influence the stock's direction.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a broader lineup that spans hundreds of strategies across thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and the symbols they trade. Investors can explore the page to see how AI-driven systems are navigating today's markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ADGM's RSI Oscillator is remaining in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ADGM just turned positive on October 13, 2026. Looking at past instances where ADGM's MACD turned positive, the stock continued to rise in 18 of 19 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADGM advanced for three days, in 77 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ADGM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADGM as a result. In 37 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADGM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ADGM entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.265) is normal, around the industry mean (4.338). P/E Ratio (-0.045) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (60.976) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ADGM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADGM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement